Abstracts Archive - Page 573 of 2607 - ACR Meeting Abstracts

Abstract Number: 1349 • ACR Convergence 2022
Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease
Maria A. Lopez-Olivo¹, Juan Ruiz², Gabrielle Duhon², Mehmet Altan³, Hussein Tawbi², Adi Diab⁴, Clifton O. Bingham III⁵, Cassandra Calabrese⁶, Natalia I. Heredia⁷, Robert J. volk² and Maria Suarez-Almazor⁸, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Johns Hopkins University, Baltimore, MD, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX, ⁸MD Anderson Cancer Center, Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) have improved cancer outcomes but can cause severe toxicity and flares in cancer patients with pre-existing autoimmune disease. The objective…
Abstract Number: 1343 • ACR Convergence 2022
Satisfaction with Rheumatoid Arthritis Care Is Related to Discordance with Providers’ Treatment Goals and Patients’ Reasons for Disagreement
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on the incidence of shared treatment goal discussions which are associated with disease activity (DA) improvement and satisfaction within rheumatology care.…
Abstract Number: 1355 • ACR Convergence 2022
Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
Marina Magrey¹, James Cheng-Chung WEI², Arne Yndestad³, Andrew Bushmakin⁴, Joseph Cappelleri⁴, Oluwaseyi Dina⁵ and Atul Deodhar⁶, ¹Case Western Reserve University, University Hospitals, Richfield, OH, ²Chung Shan Medical University Hospital, Taichung, Taiwan, ³Pfizer Inc, Oslo, Norway, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Patients (pts) with AS often experience impaired work productivity.1 In pts with AS receiving tofacitinib (oral Janus kinase inhibitor), improvements were observed in work…
Abstract Number: 1356 • ACR Convergence 2022
Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study
Camille Mettler¹, Veronique Le Guern², Paul Legendre¹, Caroline Morbieu¹, Tali-Anne Swebel¹, Xavier Puéchal³, Pascal Cohen³, Hicham Kardaoui¹, Alexandre Moores¹, Luc Mouthon³, Nathalie Costedoat-Chalumeau⁴ and Benjamin Terrier³, ¹Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Cochin Hospital, Paris, France, ²Hôpital Cochin, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Inserm DR Paris 5, Paris, France
Background/Purpose: Systemic autoimmune diseases (AID) are chronic conditions with significant burden related to the disease itself, its management, and treatments. Burden refers to the workload…
Abstract Number: 1346 • ACR Convergence 2022
“Finally, I Can Do Something About It Myself”: A Process Evaluation of the Plants for Joints Lifestyle Intervention
Carlijn Wagenaar¹, Alie Toonstra¹, Wendy Walrabenstein¹, Dirkjan van Schaardenburg² and Femke van Nassau², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: Plants for Joints (PFJ) is a multidisciplinary intervention centered around a whole-food plant-based diet, physical activity, and sleep and stress management.1 The PFJ intervention…
Abstract Number: 1354 • ACR Convergence 2022
Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application
Leslie Harrold¹, Patrick Zueger², William Benjamin Nowell³, Taylor Blachley¹, Paul Lakin¹, David Curtis⁴, Laura Stradford³, Shilpa Venkatachalam⁵, Namita Tundia² and Pankaj Patel², ¹CorEvitas, LLC, Waltham, MA, ²AbbVie, Inc., North Chicago, IL, ³Global Healthy Living Foundation, Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, New York, NY
Background/Purpose: Little is known about the impact of upadacitinib (UPA) in rheumatoid arthritis (RA) during the initial weeks of therapy in real-world clinical practice. Our…
Abstract Number: 1367 • ACR Convergence 2022
Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Brian Feldman⁷, Jordi Anton⁸, Maria Katsicas⁹, Valda Stanevica¹⁰, FLAVIO SZTAJNBOK¹¹, Simone Appenzeller¹², Tadey Avcin¹³, Mikhail Kostik¹⁴, Edoardo Marrani¹⁵, Walter Alberto Sifuentes-Giraldo¹⁶, Sindu Johnson¹⁷, Raju Khubchandani¹⁸, Dana Nemcova¹⁹, Maria José Santos²⁰, Cristina Battagliotti²¹, Lillemor Berntson²², Blanca Bica²³, Jürgen Brunner²³, Rolando Cimaz²⁴, Despina Eleftheriou²⁵, Liora Harel²⁶, Gerd Horneff²⁷, Mahesh Janarthanan²⁸, Tilmann Kallinich²⁹, Kirsten Minden³⁰, Anjali Patwardhan³¹, Dieneke Schonenberg-Meinema³², Vanessa Smith³³ and Nicola Helmus³⁴, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ⁴Cerrahpaşa Medical School, Istanbul University, Istanbul, Turkey, ⁵Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ⁶Universidad Federal São Paulo, São Paulo, Brazil, ⁷Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁸Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ⁹Hospital Garrahan, Buenos Aires, Argentina, ¹⁰Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹¹UFRJ/UERJ, São Paulo, Brazil, ¹²Unicamp, Campinas, São Paulo, Brazil, ¹³University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁴Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁵University of Florence, Firenze, Italy, ¹⁶Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸SRCC Children's Hospital, Mumbai, India, ¹⁹Charles University, Prague, Czech Republic, ²⁰Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ²¹Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²²Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²³UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ²⁴University of Milano, Milano, Italy, ²⁵Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ²⁶Schneider Children's Medical center, Tel Aviv University, Nettnja, Israel, ²⁷Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁸SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ²⁹Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ³⁰Charité Universitätsmedizin Berlin, Berlin, Germany, ³¹University of Missouri, Columbia, MO, ³²Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ³³Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium, ³⁴Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 1361 • ACR Convergence 2022
Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Asra Firdous¹, Megan Quinlan-Waters¹, Amy Cassedy², Angela Merritt¹, Hermine Brunner³, Alexei Grom¹, Daniel Lovell¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cleveland, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis and multi-organ involvement. Treatment with systemic immunosuppression…
Abstract Number: 1363 • ACR Convergence 2022
Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
Jessica Perfetto¹, Donna Yoo², Carolina Tamashiro³, Megan Perron⁴, Natalia Vasquez Canizares⁵ and Dawn Wahezi⁶, ¹The Children's Hospital at Montefiore, Division of Rheumatology, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³The Children's Hospital at Montefiore, Department of Pediatrics, Bronx, NY, ⁴Children's Hospital Colorado, Division of Rheumatology, Aurora, CO, ⁵Children's Hospital at Montefiore/ Albert Einstein College of Medicine, New York, NY, ⁶Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: Viruses can trigger juvenile idiopathic inflammatory myopathies (JIIM), including juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and overlap myositis. There is growing evidence that infection…
Abstract Number: 1359 • ACR Convergence 2022
Usability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia
Nelson Mitchell¹, Yifei Dai², Michael Rosenbluth³, Allison Kraus¹, Maggie Avila¹, Aabha Morey¹, Michael Gendreau⁴, Nicolette Vega¹, Zunera Ghalib¹ and Brian Keefe⁵, ¹Swing Therapeutics, San Francisco, ²Swing Therapeutics, Gainesville, FL, ³Swing Therapeutics, San Francisco, CA, ⁴GENDREAU CONSULTING, LLC, Poway, CA, ⁵Swing Therapeutics, New York, NY
Background/Purpose: Cognitive behavioral therapy (CBT) is considered a gold-standard treatment with demonstrated level 1A evidence for management of fibromyalgia (FM). Acceptance and Commitment Therapy (ACT),…
Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Gulnara Mamyrova¹, William Nguyen², Hassan Awal¹, Derek Jones¹, Alison Ehrlich³, Kathleen Brindle⁴, Shahriar Haji-Momenian⁴, Robert Sheets⁵, Adeline Y. Chin⁶, Shajia Lu⁷, Massimo Gadina⁷, Hanna Kim⁸, Olcay Y. Jones⁹, Lisa G Rider¹⁰ and Rodolfo V Curiel¹, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, ³Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Radiology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA, ⁶Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁷Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁰Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…
Abstract Number: 1369 • ACR Convergence 2022
Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
Tom Elena Dubov¹, Dawn Wahezi², Evin Rothschild², Tamar Rubinstein³ and Tamara Tanner⁴, ¹NYCH+H/Jacobi, Bronx, NY, ²Children's Hospital at Montefiore, Bronx, NY, ³Albert Einstein College of Medicine, White Plains, NY, ⁴Montefiore Medical Center, Bronx, NY
Background/Purpose: Exposure to sunlight has been implicated as a major contributing factor in the pathogenesis of systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM). Despite…
Abstract Number: 1371 • ACR Convergence 2022
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
Amita Aggarwal¹, Liza Rajasekhar², Parasar Ghosh³, Ashish J Mathew⁴, Chengappa Kavadichanda⁵, Vineetha Shobha⁶, Ranjan Gupta⁷, Saumya Ranjan Tripathy⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶St. John’s Medical College Hospital, Bangalore, India, ⁷All India Institute of Medical Sciences, New Delhi, India, ⁸SCB medical college, Cuttack, India, ⁹PGIMER Chandigarh, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…
Abstract Number: 1313 • ACR Convergence 2022
The Role of Tryptophan and Its Metabolites in Risk for Incident Hip Fractures and Frailty: The Cardiovascular Health Study
Laura Carbone¹, Petra Bůžková², John Robbins³, Howard Fink⁴, Joshua Barzilay⁵, Rachel Elam¹ and Carlos Isales¹, ¹Augusta University, Augusta, GA, ²University of Washington, Seattle, WA, ³UC Davis, Davis, CA, ⁴University of Minnesota, Minneapolis, MN, ⁵Kaiser Permanente, Atlanta, GA
Background/Purpose: Essential amino acids including tryptophan (trp) are building blocks for protein, and adequate protein intake is important for skeletal homeostasis. In experimental studies, trp…
Abstract Number: 1262 • ACR Convergence 2022
Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis
Irina Gessl¹, Thomas Deimel¹, Paul Studenic¹, Giorgio Tamborrini², Pascal Zufferey³, Daniel Aletaha⁴, Burkhard Moeller⁵ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Ultrasound Center and Institute for Rheumatology, Zürich, Switzerland, ³HFR, Fribourg, Switzerland, ⁴Medical University Vienna, Wien, Austria, ⁵Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: Musculoskeletal ultrasound (US) has been reported to predict radiographic progression in rheumatoid arthritis (RA). The aim of the study was to test the predictive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].